Haemonetics (HAE) 10-Q 5 Feb 15 2015 Q3 Quarterly report Financial data

DOCUMENT_AND_ENTITY_INFORMATIO

DOCUMENT AND ENTITY INFORMATION	9 Months Ended
	Dec. 27, 2014
Document And Entity Information [Abstract]
Entity Registrant Name	HAEMONETICS CORP
Entity Central Index Key	313143
Current Fiscal Year End Date	-25
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	27-Dec-14
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding	51,491,568

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013	Dec. 27, 2014	Dec. 28, 2013
Income Statement [Abstract]
Net revenues	$231,827	$242,120	$683,895	$697,418
Cost of goods sold	120,166	120,491	357,842	344,494
Gross profit	111,661	121,629	326,053	352,924
Operating expenses:
Research and development	10,643	14,209	36,962	40,364
Selling, general and administrative	82,758	89,560	260,089	277,879
Total operating expenses	93,401	103,769	297,051	318,243
Operating income	18,260	17,860	29,002	34,681
Interest and other expense, net	-2,308	-2,852	-7,496	-8,035
Income before provision for (benefit from) income taxes	15,952	15,008	21,506	26,646
Provision for (benefit from) income taxes	-36	-1,282	1,679	1,682
Net income	15,988	16,290	19,827	24,964
Net income per share - basic (in dollars per share)	$0.31	$0.31	$0.38	$0.48
Net income per share - diluted (in dollars per share)	$0.31	$0.31	$0.38	$0.48
Weighted average shares outstanding
Basic (in shares)	51,432	51,730	51,521	51,485
Diluted (in shares)	51,962	52,511	52,024	52,300
Comprehensive income	$8,346	$17,289	$10,841	$24,463

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 27, 2014	Mar. 29, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$125,200	$192,469
Accounts receivable, less allowance of $1,975 at December 27, 2014 and $1,676 at March 29, 2014	143,635	164,603
Inventories, net	212,493	197,661
Deferred tax asset, net	16,172	14,144
Prepaid expenses and other current assets	52,331	54,099
Total current assets	549,831	622,976
Net property, plant and equipment	323,491	271,437
Intangible assets, less accumulated amortization of $125,642 at December 27, 2014 and $101,694 at March 29, 2014	251,221	271,159
Goodwill	334,990	336,768
Deferred tax asset, long term	1,031	1,184
Other long-term assets	13,581	10,654
Total assets	1,474,145	1,514,178
Current liabilities:
Notes payable and current maturities of long-term debt	7,748	45,630
Accounts payable	46,830	53,562
Accrued payroll and related costs	48,028	54,913
Accrued income taxes	2,754	3,113
Other liabilities	58,980	59,710
Total current liabilities	164,340	216,928
Long-term debt, net of current maturities	421,006	392,057
Long-term deferred tax liability	25,871	29,664
Other long-term liabilities	29,020	37,641
Stockholders’ equity:
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 51,491,568 shares at December 27, 2014 and 52,041,189 shares at March 29, 2014	515	520
Additional paid-in capital	417,405	402,611
Retained earnings	423,563	433,347
Accumulated other comprehensive income	-7,575	1,410
Total stockholders’ equity	833,908	837,888
Total liabilities and stockholders’ equity	$1,474,145	$1,514,178

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Dec. 27, 2014	Mar. 29, 2014
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$1,975	$1,676
Intangible assets, amortization	$125,642	$101,694
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	51,491,568	52,041,189
Common stock, shares outstanding (in shares)	51,491,568	52,041,189

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013
Cash Flows from Operating Activities:
Net income	$19,827	$24,964
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	63,891	59,063
Amortization of financing costs	797	1,170
Stock compensation expense	10,219	9,664
Purchase of in-process R&D	0	3,569
Loss on sale of property, plant and equipment	612	501
Unrealized loss from hedging activities	1,477	351
Contingent consideration expense	706	1,182
Asset write-down	1,246	1,711
Change in accounts receivable, net	14,422	20,432
Change in inventories	-17,906	-24,627
Change in prepaid income taxes	-219	-2,124
Change in other assets and other liabilities	-18,834	5,219
Tax benefit of exercise of stock options	961	2,906
Change in accounts payable and accrued expenses	-5,326	-15,928
Net cash provided by operating activities	71,873	88,053
Cash Flows from Investing Activities:
Capital expenditures on property, plant and equipment	-100,530	-43,721
Proceeds from sale of property, plant and equipment	387	197
Acquisition of Hemerus	0	-23,124
Other acquisitions and investments	0	8,374
Net cash used in investing activities	-100,143	-75,022
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	-778	-715
Net increase in short-term loans	-357	-4,426
Repayment of term loan borrowings	-8,531	-28,531
Proceeds from employee stock purchase plan	4,763	5,229
Proceeds from exercise of stock options	7,926	11,699
Excess tax benefit on exercise of stock options	0	2,076
Share repurchases	-38,701	0
Net cash used in financing activities	-35,678	-14,668
Effect of exchange rates on cash and cash equivalents	-3,321	363
Net Change in Cash and Cash Equivalents	-67,269	-1,274
Cash and Cash Equivalents at Beginning of Period	192,469	179,120
Cash and Cash Equivalents at End of Period	125,200	177,846
Supplemental Disclosures of Cash Flow Information:
Interest paid	6,271	6,973
Income taxes paid	10,727	4,093
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$5,755	$7,967

BASIS_OF_PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Dec. 27, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION
	Our accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of our management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. All intercompany transactions have been eliminated. Operating results for the nine months ended are not necessarily indicative of the results that may be expected for the full fiscal year ending March 28, 2015, or any other interim period. Operating results for the three and nine months ended December 27, 2014 include the correction of an overstatement of operating expenses in prior periods. Absent this correction, operating expenses would have been $1.7 million higher in the three and nine months ended December 27, 2014 than the amounts included in the accompanying Consolidated Statements of Income and Comprehensive Income. This overstatement was due to an error in the computation of the restructuring accrual for severance and employee benefits incurred in connection with the Company’s ongoing Value Creation and Capture initiatives and the cost of parts used to maintain our Haemonetics owned equipment. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and footnotes included in our annual report on Form 10-K for the fiscal year ended March 29, 2014.
	We consider events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. We had no significant subsequent events.
	Our fiscal year ends on the Saturday closest to the last day of March. Fiscal years 2015 and 2014 include 52 weeks with each quarter having 13 weeks.

RECENT_ACCOUNTING_PRONOUNCEMEN

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Dec. 27, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS
	In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. ASU No. 2014-08 limits the requirement to report discontinued operations to disposals of components of an entity that represent strategic shifts that have (or will have) a major effect on an entity’s operations and financial results. The amendments also require expanded disclosures concerning discontinued operations and disclosures of certain financial results attributable to a disposal of a significant component of an entity that does not qualify for discontinued operations reporting. The amendments in ASU No. 2014-08 are effective prospectively for reporting periods beginning on or after December 15, 2014, with early adoption permitted. Management does not believe that the adoption of ASU No. 2014-08 will have a material effect on our Financial Statements.
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU No. 2014-09 stipulates that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU No. 2014-09 will be effective for the Company retrospectively beginning April 2, 2017, with early adoption not permitted. The impact of adopting ASU No. 2014-09 on our Financial Statements is being assessed by management.
	In June 2014, the FASB issued ASU No. 2014-12, Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. ASU No. 2014-12 requires that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC 718, Compensation—Stock Compensation, as it relates to such awards. ASU No. 2014-12 is effective in our first quarter of fiscal 2017 with early adoption permitted using either of two methods: (i) prospective to all awards granted or modified after the effective date; or (ii) retrospective to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter, with the cumulative effect of applying ASU No. 2014-12 as an adjustment to the opening retained earnings balance as of the beginning of the earliest annual period presented in the financial statements. Management does not believe that the adoption of ASU No. 2014-12 will have a material effect on our Financial Statements.
	In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU No. 2014-15 defines management's responsibility to assess an entity's ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. This guidance will be effective for all entities in the first annual period ending after December 15, 2016; however, early adoption is permitted. Management does not believe that the adoption of ASU No. 2014-15 will have a material effect on our Financial Statements.
	In January 2015, the FASB issued ASU No. 2015-01, Income Statement-Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items. ASU No. 2015-01 eliminates from GAAP the concept of extraordinary items. An entity will no longer be required to (1) segregate an extraordinary item from the results of ordinary operations; (2) separately present an extraordinary item on its income statement, net of tax, after income from continuing operations; and (3) disclose income taxes and earnings-per-share data applicable to an extraordinary item. ASU No. 2015-01 will be effective for fiscal years beginning after December 15, 2015. An entity may apply the amendments prospectively or retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. Management does not believe that the adoption of ASU No. 2015-01 will have a material effect on our Financial Statements.

EARNINGS_PER_SHARE_EPS

EARNINGS PER SHARE ("EPS")	9 Months Ended
	Dec. 27, 2014
Earnings Per Share [Abstract]
EARNINGS PER SHARE (EPS)	EARNINGS PER SHARE (“EPS”)
	The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.
		Three Months Ended
	(In thousands, except per share amounts)	December 27,		December 28,
		2014		2013
	Basic EPS
	Net income	$	15,988	$	16,290
	Weighted average shares	51,432		51,730
	Basic income per share	$	0.31	$	0.31
	Diluted EPS
	Net income	$	15,988	$	16,290
	Basic weighted average shares	51,432		51,730
	Net effect of common stock equivalents	530		781
	Diluted weighted average shares	51,962		52,511
	Diluted income per share	$	0.31	$	0.31
		Nine Months Ended
	(In thousands, except per share amounts)	December 27,		December 28,
		2014		2013
	Basic EPS
	Net income	$	19,827	$	24,964
	Weighted average shares	51,521		51,485
	Basic income per share	$	0.38	$	0.48
	Diluted EPS
	Net income	$	19,827	$	24,964
	Basic weighted average shares	51,521		51,485
	Net effect of common stock equivalents	503		815
	Diluted weighted average shares	52,024		52,300
	Diluted income per share	$	0.38	$	0.48
	Weighted average shares outstanding, assuming dilution, excludes the impact of 1.7 million and 1.6 million anti-dilutive shares for the three and nine months ended December 27, 2014, respectively, as compared to 1.3 million and 0.9 million anti-dilutive shares for the three and nine months ended December 28, 2013, respectively.

STOCKBASED_COMPENSATION

STOCK-BASED COMPENSATION

9 Months Ended

Dec. 27, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION

Performance Share Units

On October 22, 2014, the Company issued a new type of equity award under its 2005 Long-Term Incentive Compensation Plan, Performance Share Units, with a target award level of 129,130 shares for 14 senior executives.

The value of these Performance Share Units is based upon the Company’s total shareholder return for the period from October 1, 2014 to their vesting date of September 30, 2017 relative to the total shareholder return of the companies comprising the Standard & Poor's Health Care Equipment Index (the "Index"). These awards are conditioned upon the employees’ continued employment with the Company through the vesting date. If an employee is no longer employed by the Company at the vesting date as a result of a Qualifying Retirement, then the continued employment requirement shall cease to apply and prorated shares awarded will be determined as of the vesting date.

Total shareholder return is equal to the appreciation of the share price during a performance period, plus any dividends paid on the applicable company’s common stock. Relative total shareholder return compares the company's total shareholder return to the Index.

The actual number of shares awarded under a Performance Share Unit may range from 0% to a maximum of 200% of the target award depending upon the Company’s relative total shareholder return. If the Company’s total shareholder return for the performance period is negative, then any share payout will be capped at 100% of the target award, regardless of the Company's performance relative to the Index.

Grant date fair values for the Performance Share Units were estimated using a Monte Carlo Simulation of the Company's and the Index's stock price correlation over three-year time horizons matching the Performance Share Units performance period with a risk free rate of 0.78%, volatility of 20% and 12 months of dividend history.

The estimated fair value, potential shares to be awarded, recognized compensation expense and future compensation expense to be recognized, including estimated forfeitures, for Performance Share Unit awards are as follows:

As of October 22, 2014

For Nine Months Ended December 27, 2014

PSU Performance Period

PSU Award Fair Value

Recognized Compensation Expense

Unrecognized Compensation Expense

Minimum Shares

Target Shares

Maximum Shares

(Per share)

(In thousands)

(In thousands)

Oct 1, 2014 - Sept 30, 2017

$

35.09

$

278

$

4,253

—

129,130

258,260

Stock-Based Compensation

Total stock-based compensation expense of $10.2 million and $9.7 million was recognized for the nine months ended December 27, 2014 and December 28, 2013, respectively. The related income tax benefit recognized was $3.3 million and $3.2 million for the nine months ended December 27, 2014 and December 28, 2013, respectively.

The weighted average fair value for our options granted was $7.89 and $10.17 per share for the nine months ended December 27, 2014 and December 28, 2013, respectively. The assumptions utilized for estimating the fair value of option grants during the periods presented are as follows:

Nine Months Ended

December 27,

December 28,

2014

2013

Stock Options Black-Scholes assumptions (weighted average):

Volatility

22.45

%

22.79

%

Expected life (years)

4.9

4.9

Risk-free interest rate

1.75

%

1.3

%

Dividend yield

—

%

—

%

As of December 27, 2014, there was $29.0 million of total unrecognized compensation cost related to non-vested equity based compensation, including stock options, restricted stock units, market stock units and performance share units. This cost is expected to be recognized over a weighted average period of 2.61 years.

During the nine months ended December 27, 2014 and December 28, 2013, there were 183,808 and 156,224 shares, respectively, purchased under the Employee Stock Purchase Plan at an average price of $25.92 and $32.77 per share, respectively.

PRODUCT_WARRANTIES

PRODUCT WARRANTIES	9 Months Ended
	Dec. 27, 2014
Product Warranties Disclosures [Abstract]
PRODUCT WARRANTIES	PRODUCT WARRANTIES
	We generally provide warranty on parts and labor for one year after the sale and installation of each device. We also warrant our disposables products through their use or expiration. We estimate our potential warranty expense based on our historical warranty experience and periodically assess the adequacy of our warranty accrual, making adjustments as necessary.
		Nine Months Ended
	(In thousands)	December 27,			December 28,
		2014			2013
	Warranty accrual as of the beginning of the period	$	590		$	673
	Warranty provision	890			1,214
	Warranty spending	(941		)	(1,178		)
	Warranty accrual as of the end of the period	$	539		$	709

INVENTORIES

INVENTORIES	9 Months Ended
	Dec. 27, 2014
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES
	Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined using the first-in, first-out method.
	(In thousands)	December 27,		March 29,
		2014		2014
	Raw materials	$	74,555	$	72,508
	Work-in-process	6,431		7,383
	Finished goods	131,507		117,770
		$	212,493	$	197,661

DERIVATIVES_AND_FAIR_VALUE_MEA

DERIVATIVES AND FAIR VALUE MEASUREMENTS	9 Months Ended
	Dec. 27, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVES AND FAIR VALUE MEASUREMENTS	DERIVATIVES AND FAIR VALUE MEASUREMENTS
	We manufacture, market and sell our products globally. For the nine months ended December 27, 2014, approximately 45.9% of our sales were generated outside the US, generally in local currencies. We also incur certain manufacturing, marketing and selling costs in international markets in local currency.
	Accordingly, our earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the US Dollar, our reporting currency. We have a program in place that is designed to mitigate our exposure to changes in foreign currency exchange rates. We utilize foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily Japanese Yen and Euro, and to a lesser extent Swiss Francs, British Pounds, Australian Dollars, Canadian Dollars and Mexican Pesos. This does not eliminate the impact of the volatility of foreign exchange rates, but because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.
	Designated Foreign Currency Hedge Contracts
	Our designated foreign currency hedge contracts as of December 27, 2014 and March 29, 2014 were cash flow hedges under ASC 815, Derivatives and Hedging. We record the effective portion of any change in the fair value of designated foreign currency hedge contracts in Other Comprehensive Income until the related third-party transaction occurs. Once the related third-party transaction occurs, we reclassify the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, we would reclassify the amount of any gain or loss on the related cash flow hedge to Retained Earnings at that time. We had designated foreign currency hedge contracts outstanding in the contract amount of $147.4 million as of December 27, 2014 and $157.9 million as of March 29, 2014.
	During the nine months ended December 27, 2014, we recognized net gains of $2.9 million in Retained Earnings from our cash flow hedges, compared to recognized net gains of $7.1 million during the nine months ended December 28, 2013. For the nine months ended December 27, 2014, an $8.4 million gain, net of tax, was recorded in Accumulated Other Comprehensive Income to recognize the effective portion of the fair value of designated foreign currency hedge contracts, as compared to a gain of $5.0 million, net of tax, for the nine months ended December 28, 2013. At December 27, 2014, gains of $8.4 million, net of tax, may be reclassified to Retained Earnings within the next twelve months. All currency cash flow hedges outstanding as of December 27, 2014 mature within twelve months.
	Non-Designated Foreign Currency Contracts
	We use foreign currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC 815. These forward contracts are marked-to-market with changes in fair value recorded to Retained Earnings. We had non-designated foreign currency hedge contracts under ASC 815 outstanding in the contract amount of $60.4 million as of December 27, 2014 and $72.9 million as of March 29, 2014.
	Interest Rate Swaps
	On August 1, 2012, we entered into a credit agreement which provided for a $475.0 million term loan (“Credit Agreement”). Under the terms of this Credit Agreement, we may borrow at a spread to an index, including the LIBOR index of 1-month, 3-months, 6-months, etc. From the date of the Credit Agreement, we have chosen to borrow against the 1-month USD-LIBOR-BBA rounded up, if necessary, to the nearest 1/16th of 1% (“Adjusted LIBOR”). On June 30, 2014, we modified our Credit Agreement by extending the maturity date to July 1, 2019.
	Accordingly, our earnings and cash flows are exposed to interest rate risk from changes in Adjusted LIBOR. Part of our interest rate risk management strategy includes the use of interest rate swaps to mitigate our exposure to changes in variable interest rates. Our objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations. We formally document our hedge relationships (including identifying the hedged instrument and hedged item) at hedge inception to ensure that our interest rate swaps qualify for hedge accounting. On a quarterly basis, we assess whether the interest rate swaps are highly effective in offsetting changes in the cash flow of the hedged item. We do not hold or issue interest rate swaps for trading purposes. We manage the credit risk of the counterparties by dealing only with institutions that we consider financially sound and consider the risk of non-performance to be remote.
	On December 21, 2012, we entered into two interest rate swap agreements (the "Swaps"), whereby we receive Adjusted LIBOR and pay an average fixed rate of 0.68% on a total notional amount of $250.0 million of debt. The Swaps mature on August 1, 2017. We designated the Swaps as cash flow hedges of variable interest rate risk associated with $250.0 million of indebtedness. For the nine months ended December 27, 2014, a loss of $0.3 million, net of tax, was recorded in Accumulated Other Comprehensive Income to recognize the effective portion of the fair value of interest rate swaps that qualify as cash flow hedges.
	Fair Value of Derivative Instruments
	The following table presents the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in our consolidated statements of income and comprehensive income for the nine months ended December 27, 2014:
	Derivative Instruments		Amount of				Amount of Gain/(Loss) Reclassified				Location in		Amount of Gain/(Loss)				Location in
			Gain/(Loss)				from AOCI into				Consolidated Statements of		Excluded from				Consolidated Statements of
			Recognized				Retained Earnings				Income and Comprehensive Income		Effectiveness				Income and Comprehensive Income
			in AOCI										Testing *
	(In thousands)
	Designated foreign currency hedge contracts, net of tax		$	8,409			$	2,921			Net revenues, COGS, and SG&A		$	107			Interest and other expense, net
	Non-designated foreign currency hedge contracts		—				—						5,477				Interest and other expense, net
	Designated interest rate swaps, net of tax		$	(255	)		$	—			Interest and other expense, net		$	—
	*   We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.
	We did not have fair value hedges or net investment hedges outstanding as of December 27, 2014 or March 29, 2014.
	As of December 27, 2014, the amount recognized as a deferred tax asset for designated foreign currency hedges was $0.5 million and the amount recognized as a deferred tax liability for interest rate swap hedges was $0.3 million.
	ASC 815 requires all derivative instruments to be recognized at their fair value as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by ASC 820, Fair Value Measurements and Disclosures, by considering the estimated amount we would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. Generally, we use inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of December 27, 2014, we have classified our derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC 815, as discussed below, because these observable inputs are available for substantially the full term of our derivative instruments.
	The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of December 27, 2014 and March 29, 2014:
	(In thousands)		Location in		December 27, 2014				March 29, 2014
			Balance Sheet
	Derivative Assets:
	Designated foreign currency hedge contracts		Other current assets		$	8,088			$	2,574
	Designated interest rate swaps		Other current assets		841				1,250
					$	8,929			$	3,824
	Derivative Liabilities:
	Designated foreign currency hedge contracts		Other current liabilities		$	2,465			$	1,255
					$	2,465			$	1,255
	Other Fair Value Measurements
	ASC 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in accordance with US GAAP, and expands disclosures about fair value measurements. ASC 820 does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or permit fair value measurements. In accordance with ASC 820, for the nine months ended December 27, 2014, we applied the requirements under ASC 820 to our non-financial assets and non-financial liabilities. As we did not have an impairment of any non-financial assets or non-financial liabilities, there was no disclosure required relating to our non-financial assets or non-financial liabilities.
	Fair Value Measured on a Recurring Basis
	On a recurring basis, we measure certain financial assets and financial liabilities at fair value, including our money market funds, foreign currency hedge contracts, and contingent consideration. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. We base fair value upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value.
	ASC 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
	•	Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
	•	Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
	•	Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
	Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of December 27, 2014.
	(In thousands)		Quoted Market				Significant				Significant				Total
			Prices for				Other				Unobservable
			Identical Assets				Observable				Inputs
			(Level 1)				Inputs				(Level 3)
							(Level 2)
	Assets
	Money market funds		$	72,875			$	—			$	—			$	72,875
	Designated foreign currency hedge contracts		—				8,088				—				8,088
	Designated interest rate swap		—				841				—				841
			$	72,875			$	8,929			$	—			$	81,804
	Liabilities
	Designated foreign currency hedge contracts		$	—			$	2,465			$	—			$	2,465
	Contingent consideration		—				—				8,351				8,351
			$	—			$	2,465			$	8,351			$	10,816
	Our money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.
	Contingent consideration liabilities are measured at fair value using projected revenues, discount rates, probabilities of payment and projected payment dates. This Level 3 fair value measurement was performed using a probability-weighted discounted cash flow over a ten year period. Increases or decreases in the fair value of our contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing and amount of revenue estimates or likelihood of earning revenue. Projected revenues are based on our most recent internal operational budgets.
	The table below provides a reconciliation of the beginning and ending Level 3 liabilities for the quarter ended December 27, 2014.
	(In thousands)		Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Contingent consideration as of March 29, 2014		$	7,645
Contingent consideration interest expense		706
Ending balance		$	8,351
Interest expense recognized on contingent consideration is reflected in "Interest and other expense, net" on the
Consolidated Statements of Income and Comprehensive Income.
Other Fair Value Disclosures
The Term Loan (which is carried at amortized cost), accounts receivable and accounts payable approximate fair value.

INCOME_TAXES

INCOME TAXES	9 Months Ended
	Dec. 27, 2014
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES
	The reported income tax rate for the nine months ended December 27, 2014 was 7.8%, as compared to a reported income tax rate of 6.3% for the nine months ended December 28, 2013. Our reported income tax rate is lower than the US federal statutory tax rate primarily as a result of being subject to lower income tax rates in the foreign jurisdictions where we operate. In addition, we recorded discrete tax benefits during the three months ended December 27, 2014 associated with the release of tax reserves due to the expiration of the statute of limitations as well as the retroactive enactment of the U.S. federal research credit. During the nine months ended December 27, 2014, we recorded pre-tax losses in Scotland, Italy and Malaysia due to restructuring costs associated with our manufacturing transformation, and we did not record a corresponding tax benefit due to uncertainty around our ability to realize a tax benefit in these jurisdictions. Similarly, during the nine months ended December 28, 2013, we recorded pre-tax losses in Italy associated with restructuring costs, and we did not recognize a tax benefit due to the full valuation allowance maintained against our Italian deferred tax assets. We also recorded a tax benefit for the three months ended December 28, 2013 as the benefits from the release of previously established reserves and the intercompany financing with Italy were recorded during this period.

DEBT

DEBT	9 Months Ended
	Dec. 27, 2014
Debt Disclosure [Abstract]
DEBT	DEBT
	In connection with the acquisition of the whole blood business, we entered into a credit agreement ("Credit Agreement") with certain lenders (together, “Lenders”) which provided for a $475.0 million Term Loan and a $50.0 million revolving loan (the “Revolving Credit Facility”), and together with the Term Loan, (the “Credit Facilities”). The Credit Facilities had a term of five years and mature on August 1, 2017. Interest was based on the Adjusted LIBOR plus a range of 1.125% to 1.500% depending on the achievement of leverage ratios and customary credit terms which included financial and negative covenants.
	On June 30, 2014, we modified our existing Credit Facilities by extending the maturity date to July 1, 2019, extending the principal repayments of the Term Loan, and modifying certain restrictive covenants to allow greater operational flexibility and enhanced near term liquidity. In addition, the amended Credit Agreement provides for a $100.0 million revolving credit facility and establishes interest rates in the range of LIBOR plus 1.125% – 1.500%, depending on certain conditions. At December 27, 2014, $379.4 million was outstanding under the term loan and $50.0 million was outstanding on the Revolving Credit Facility, both with an interest rate of 1.5625%. No additional amounts were borrowed as a result of this modification. The fair value of debt approximates its current value of approximately $429.4 million as of December 27, 2014. We were in compliance with the leverage and interest coverage ratios specified in the credit agreement as well as all other bank covenants as of December 27, 2014.
	The maturity profile is as follows:
	Fiscal year (in thousands)	Term Loan
	2015	$	—
	2016	21,342
	2017	42,683
	2018	45,054
	2019 and beyond	320,327
		$	429,406

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Dec. 27, 2014
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES
	We are presently engaged in various legal actions, and although the total liability cannot be determined at the present time, based on consultation with counsel, we believe that any such liability will not materially affect our consolidated financial position or our results of operations.
	Italian Employment Litigation
	We have received notices of claimed violations of employment related contracts from some employees of the facility in Ascoli-Piceno, Italy where we have ceased manufacturing operations. These include actions claiming (i) working conditions and minimum salaries should have been established by different national collective bargaining agreements than those used over prior years, (ii) certain solidarity agreements, which are arrangements between the Company, employees and the government to continue full pay and benefits for employees who would otherwise be terminated in times of low demand, are void, and (iii) payment of the extra time used for changing into and out of the working clothes at the beginning and end of each shift.
	In addition, a union represented in the Ascoli plant has filed an action claiming that the Company discriminated against it in favor of three other represented unions by (i) interfering with an employee referendum, (ii) interfering with an employee petition to recall union representatives from office, and (iii) excluding the union from certain meetings.
	As of December 27, 2014, the total amount of damages claimed by the plaintiffs in these matters is approximately $4.1 million; however, it is not possible at this point in the proceedings to accurately evaluate the likelihood or amount of any potential losses. We believe these claims are without merit, and intend to defend against them. As such, no amounts have been accrued related to these claims. We may receive other, similar claims in the future.

SEGMENT_INFORMATION

SEGMENT INFORMATION	9 Months Ended
	Dec. 27, 2014
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION
	We manage a global business which designs, manufactures and markets blood management solutions.  Our solutions are marketed through operating units organized primarily on geography: North America Plasma, North America Blood Center and Hospital, Europe, Asia Pacific and Japan.
	ASC 280, Segment Reporting, permits the aggregation of segments which are economically similar as well as similar in all of the following areas: (i) the nature of the products and services, (ii) the nature of the production processes, (iii) the type or class of customer for their products and services, (iv) the methods used to distribute their products or provide their services, and (v) the nature of the regulatory environment.
	Based on the criteria of ASC 280, we have one reportable segment. This conclusion is consistent with how our chief operating decision-maker views the business. Our chief operating decision maker primarily uses consolidated results to make operating and strategic decisions.

RESTRUCTURING

RESTRUCTURING	9 Months Ended
	Dec. 27, 2014
Restructuring and Related Activities [Abstract]
RESTRUCTURING	RESTRUCTURING
	On an ongoing basis, we review the global economy, the healthcare industry and the markets in which we compete to identify opportunities for efficiencies, enhance commercial capabilities, align our resources and offer our customers better solutions. In order to realize these opportunities, we undertake restructuring-type activities to transform our business.
	On May 1, 2013, we announced that our Board of Directors approved a plan to pursue identified Value Creation and Capture ("VCC") opportunities. These include: (i) investment in product line extensions, next generation products and growth platforms; (ii) enhancement of commercial execution capabilities by implementing go-to-market and other strategies to enable global profitable revenue growth; and (iii) transformation of the manufacturing network to best support these commercial strategies while optimizing expense levels. Collectively, these are opportunities to position us for optimal growth and increased competitiveness.
	Our manufacturing network transformation plan, part of our larger VCC activities previously discussed, includes (i) discontinuing manufacturing activities at our Braintree, Massachusetts, Ascoli-Piceno, Italy and Bothwell, Scotland facilities, (ii) creating a technology center of excellence for product development in Braintree, Massachusetts, (iii) expanding of our current facility in Tijuana, Mexico, (iv) engaging Sanmina Corporation as a contract manufacturer to produce certain medical equipment, and (v) building a new manufacturing facility in Penang, Malaysia closer to our customers in Asia.
	We estimate we will incur approximately $69.0 million in restructuring and restructuring related expense and spend approximately $59.0 million on these initiatives in fiscal 2015. We estimate we will incur an additional $10.0 million to $15.0 million to complete these initiatives through fiscal 2017.
	The following summarizes the restructuring costs for the nine months ended December 27, 2014 and December 28, 2013:
		Nine Months Ended December 27, 2014
	(In thousands)		Restructuring Accrual Balance at March 29, 2014		Restructuring Costs Incurred		Less Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at December 27, 2014
	Severance and other employee costs		$	22,908	$	15,633	$	(21,785	)	$	—		$	16,756
	Other costs		728		12,044		(12,527		)	—			245
	Accelerated depreciation		—		1,158		—			(1,158		)	—
	Asset write-down		—		295		—			(295		)	—
	Total		$	23,636	$	29,130	$	(34,312	)	$	(1,453	)	$	17,001
		Nine Months Ended December 28, 2013
	(in thousands)		Restructuring Accrual Balance at March 30, 2013		Restructuring Costs Incurred		Less Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at December 28, 2013
	Severance and other employee costs		$	3,089	$	28,189	$	(9,690	)	$	—		$	21,588
	Other costs		173		9,905		(9,566		)	—			512
	Accelerated depreciation		—		1,757		—			(1,757		)	—
	Asset write-down		—		915		—			(915		)	—
			$	3,262	$	40,766	$	(19,256	)	$	(2,672	)	$	22,100
	We deployed significant financial resources for these activities.  Many of the costs necessary to complete the VCC initiatives, such as severance and other plant closing costs, qualify as restructuring expenses under ASC 420, Exit or Disposal Cost Obligations.  We incurred $29.1 million in severance, asset write-downs and other restructuring charges during the nine months ended December 27, 2014. In addition, we also incurred $22.1 million of costs that do not constitute restructuring under ASC 420, which we refer to as "Transformation Costs". These costs consist primarily of expenditures directly related to our transformation activities including program management, product line transfer teams and related costs, infrastructure related costs, accelerated depreciation and asset disposals.
	The table below presents transformation and restructuring costs recorded in cost of goods sold, research and development, selling, general and administrative expenses and interest and other expense in our Consolidated Statements of Income and Comprehensive Income for the periods presented. The majority of expenses recorded as Transformation Costs in the fiscal 2014 relate to the integration of the whole blood acquisition. Transformation Costs in fiscal 2015 are associated with our VCC initiatives.
	Transformation costs		Three Months Ended				Nine Months Ended
	(in thousands)		December 27,		December 28,		December 27,			December 28,
			2014		2013		2014			2013
	Transformation and other costs		$	5,892	$	6,306	$	20,877		$	26,389
	Accelerated depreciation		351		653		769			1,938
	Asset disposal		471		36		471			796
	Total		$	6,714	$	6,995	$	22,117		$	29,123
	Restructuring costs		Three Months Ended				Nine Months Ended
	(in thousands)		December 27,		December 28,		December 27,			December 28,
			2014		2013		2014			2013
	Severance and other employee costs		$	2,887	$	5,348	$	15,633		$	28,189
	Other costs		2,691		4,588		12,044			9,905
	Accelerated depreciation		418		569		1,158			1,757
	Asset disposal		199		—		295			915
	Total		$	6,195	$	10,505	$	29,130		$	40,766
	Total restructuring and transformation		$	12,909	$	17,500	$	51,247		$	69,889

CAPITALIZATION_OF_SOFTWARE_DEV

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	9 Months Ended
	Dec. 27, 2014
Research and Development [Abstract]
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS
	For costs incurred related to the development of software to be sold, leased or otherwise marketed, we apply the provisions of ASC 985-20, Software - Costs of Software to be Sold, Leased or Marketed, which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers.
	We capitalized $6.6 million and $3.4 million in software development costs for ongoing initiatives during the nine months ended December 27, 2014 and December 28, 2013, respectively. At December 27, 2014 and March 29, 2014, we have a total of $38.3 million and $31.7 million of capitalized software costs, of which $8.9 million and $15.6 million are related to in-process software development initiatives, respectively. During fiscal 2015, our next generation plasma software received 510(k) approval and $12.9 million of capitalized costs were placed into service. The costs capitalized for each project are included in intangible assets in the consolidated financial statements. We review these assets for impairment at least annually.

ACCUMULATED_OTHER_COMPREHENSIV

ACCUMULATED OTHER COMPREHENSIVE INCOME	9 Months Ended
	Dec. 27, 2014
Stockholders' Equity Note [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME	ACCUMULATED OTHER COMPREHENSIVE INCOME
	The following is a roll-forward of the components of Accumulated Other Comprehensive Income, net of tax, for the nine months ended December 27, 2014:
	(In thousands)	Foreign Currency			Defined Benefit Plans			Net Unrealized (Gain)/Loss on Derivatives			Total
	Balance as of March 29, 2014	$	3,198		$	(4,592	)	$	2,804		$	1,410
	Other comprehensive income (loss)/income before reclassifications	(13,621		)	(597		)	8,154			(6,064		)
	Amounts reclassified from Accumulated Other Comprehensive Income	—			—			(2,921		)	(2,921		)
	Net current period other comprehensive (loss)/income	(13,621		)	(597		)	5,233			(8,985		)
	Balance as of December 27, 2014	$	(10,423	)	$	(5,189	)	$	8,037		$	(7,575	)
	Details pertaining to the amount reclassified from Accumulated Other Comprehensive Income for the nine months ended December 27, 2014 are as follows:
	(In thousands)	Amounts Reclassified from Other Comprehensive Income			Affected Line in the
					Statement of Income
	Derivative instruments reclassified to income statement
	Realized net gain on derivatives	$	3,041		Revenue, cost of goods sold, income/(expense)
	Income tax effect	(120		)	Provision for income taxes
	Net of taxes	$	2,921

EARNINGS_PER_SHARE_EPS_Tables

EARNINGS PER SHARE ("EPS") (Tables)	9 Months Ended
	Dec. 27, 2014
Earnings Per Share [Abstract]
Schedule of Earnings Per Share Reconciliation	The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.
		Three Months Ended
	(In thousands, except per share amounts)	December 27,		December 28,
		2014		2013
	Basic EPS
	Net income	$	15,988	$	16,290
	Weighted average shares	51,432		51,730
	Basic income per share	$	0.31	$	0.31
	Diluted EPS
	Net income	$	15,988	$	16,290
	Basic weighted average shares	51,432		51,730
	Net effect of common stock equivalents	530		781
	Diluted weighted average shares	51,962		52,511
	Diluted income per share	$	0.31	$	0.31
		Nine Months Ended
	(In thousands, except per share amounts)	December 27,		December 28,
		2014		2013
	Basic EPS
	Net income	$	19,827	$	24,964
	Weighted average shares	51,521		51,485
	Basic income per share	$	0.38	$	0.48
	Diluted EPS
	Net income	$	19,827	$	24,964
	Basic weighted average shares	51,521		51,485
	Net effect of common stock equivalents	503		815
	Diluted weighted average shares	52,024		52,300
	Diluted income per share	$	0.38	$	0.48

STOCKBASED_COMPENSATION_Tables

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Dec. 27, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Performance Share Unit Awards	The estimated fair value, potential shares to be awarded, recognized compensation expense and future compensation expense to be recognized, including estimated forfeitures, for Performance Share Unit awards are as follows:
		As of October 22, 2014			For Nine Months Ended December 27, 2014
	PSU Performance Period	PSU Award Fair Value			Recognized Compensation Expense			Unrecognized Compensation Expense		Minimum Shares	Target Shares	Maximum Shares
		(Per share)			(In thousands)			(In thousands)
	Oct 1, 2014 - Sept 30, 2017	$	35.09		$	278		$	4,253	—	129,130	258,260
Assumptions Utilized for Estimating Fair Value of Option Grants	The assumptions utilized for estimating the fair value of option grants during the periods presented are as follows:
			Nine Months Ended
			December 27,			December 28,
			2014			2013
	Stock Options Black-Scholes assumptions (weighted average):
	Volatility		22.45	%		22.79	%
	Expected life (years)		4.9			4.9
	Risk-free interest rate		1.75	%		1.3	%
	Dividend yield		—	%		—	%

PRODUCT_WARRANTIES_Tables

PRODUCT WARRANTIES (Tables)	9 Months Ended
	Dec. 27, 2014
Product Warranties Disclosures [Abstract]
Schedule of Product Warranty Liability	We estimate our potential warranty expense based on our historical warranty experience and periodically assess the adequacy of our warranty accrual, making adjustments as necessary.
		Nine Months Ended
	(In thousands)	December 27,			December 28,
		2014			2013
	Warranty accrual as of the beginning of the period	$	590		$	673
	Warranty provision	890			1,214
	Warranty spending	(941		)	(1,178		)
	Warranty accrual as of the end of the period	$	539		$	709

INVENTORIES_Tables

INVENTORIES (Tables)	9 Months Ended
	Dec. 27, 2014
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined using the first-in, first-out method.
	(In thousands)	December 27,		March 29,
		2014		2014
	Raw materials	$	74,555	$	72,508
	Work-in-process	6,431		7,383
	Finished goods	131,507		117,770
		$	212,493	$	197,661

DERIVATIVES_AND_FAIR_VALUE_MEA1

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Dec. 27, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments	The following table presents the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in our consolidated statements of income and comprehensive income for the nine months ended December 27, 2014:
	Derivative Instruments	Amount of				Amount of Gain/(Loss) Reclassified				Location in		Amount of Gain/(Loss)				Location in
		Gain/(Loss)				from AOCI into				Consolidated Statements of		Excluded from				Consolidated Statements of
		Recognized				Retained Earnings				Income and Comprehensive Income		Effectiveness				Income and Comprehensive Income
		in AOCI										Testing *
	(In thousands)
	Designated foreign currency hedge contracts, net of tax	$	8,409			$	2,921			Net revenues, COGS, and SG&A		$	107			Interest and other expense, net
	Non-designated foreign currency hedge contracts	—				—						5,477				Interest and other expense, net
	Designated interest rate swaps, net of tax	$	(255	)		$	—			Interest and other expense, net		$	—
	*   We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.
Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets	The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of December 27, 2014 and March 29, 2014:
	(In thousands)	Location in		December 27, 2014				March 29, 2014
		Balance Sheet
	Derivative Assets:
	Designated foreign currency hedge contracts	Other current assets		$	8,088			$	2,574
	Designated interest rate swaps	Other current assets		841				1,250
				$	8,929			$	3,824
	Derivative Liabilities:
	Designated foreign currency hedge contracts	Other current liabilities		$	2,465			$	1,255
				$	2,465			$	1,255
Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis	Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of December 27, 2014.
	(In thousands)	Quoted Market				Significant				Significant				Total
		Prices for				Other				Unobservable
		Identical Assets				Observable				Inputs
		(Level 1)				Inputs				(Level 3)
						(Level 2)
	Assets
	Money market funds	$	72,875			$	—			$	—			$	72,875
	Designated foreign currency hedge contracts	—				8,088				—				8,088
	Designated interest rate swap	—				841				—				841
		$	72,875			$	8,929			$	—			$	81,804
	Liabilities
	Designated foreign currency hedge contracts	$	—			$	2,465			$	—			$	2,465
	Contingent consideration	—				—				8,351				8,351
		$	—			$	2,465			$	8,351			$	10,816
Schedule of Fair Value Measurements Using Significant Unobservable Inputs (Level 3)	The table below provides a reconciliation of the beginning and ending Level 3 liabilities for the quarter ended December 27, 2014.
	(In thousands)	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Contingent consideration as of March 29, 2014	$	7,645
	Contingent consideration interest expense	706
	Ending balance	$	8,351

DEBT_Tables

DEBT (Tables)	9 Months Ended
	Dec. 27, 2014
Debt Disclosure [Abstract]
Schedule of Maturities of Long-term Debt	The maturity profile is as follows:
	Fiscal year (in thousands)	Term Loan
	2015	$	—
	2016	21,342
	2017	42,683
	2018	45,054
	2019 and beyond	320,327
		$	429,406

RESTRUCTURING_Tables

RESTRUCTURING (Tables)	9 Months Ended
	Dec. 27, 2014
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve by Type of Cost	The following summarizes the restructuring costs for the nine months ended December 27, 2014 and December 28, 2013:
		Nine Months Ended December 27, 2014
	(In thousands)		Restructuring Accrual Balance at March 29, 2014		Restructuring Costs Incurred		Less Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at December 27, 2014
	Severance and other employee costs		$	22,908	$	15,633	$	(21,785	)	$	—		$	16,756
	Other costs		728		12,044		(12,527		)	—			245
	Accelerated depreciation		—		1,158		—			(1,158		)	—
	Asset write-down		—		295		—			(295		)	—
	Total		$	23,636	$	29,130	$	(34,312	)	$	(1,453	)	$	17,001
		Nine Months Ended December 28, 2013
	(in thousands)		Restructuring Accrual Balance at March 30, 2013		Restructuring Costs Incurred		Less Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at December 28, 2013
	Severance and other employee costs		$	3,089	$	28,189	$	(9,690	)	$	—		$	21,588
	Other costs		173		9,905		(9,566		)	—			512
	Accelerated depreciation		—		1,757		—			(1,757		)	—
	Asset write-down		—		915		—			(915		)	—
			$	3,262	$	40,766	$	(19,256	)	$	(2,672	)	$	22,100
Schedule of Restructuring and Related Costs	The table below presents transformation and restructuring costs recorded in cost of goods sold, research and development, selling, general and administrative expenses and interest and other expense in our Consolidated Statements of Income and Comprehensive Income for the periods presented. The majority of expenses recorded as Transformation Costs in the fiscal 2014 relate to the integration of the whole blood acquisition. Transformation Costs in fiscal 2015 are associated with our VCC initiatives.
	Transformation costs		Three Months Ended				Nine Months Ended
	(in thousands)		December 27,		December 28,		December 27,			December 28,
			2014		2013		2014			2013
	Transformation and other costs		$	5,892	$	6,306	$	20,877		$	26,389
	Accelerated depreciation		351		653		769			1,938
	Asset disposal		471		36		471			796
	Total		$	6,714	$	6,995	$	22,117		$	29,123
	Restructuring costs		Three Months Ended				Nine Months Ended
	(in thousands)		December 27,		December 28,		December 27,			December 28,
			2014		2013		2014			2013
	Severance and other employee costs		$	2,887	$	5,348	$	15,633		$	28,189
	Other costs		2,691		4,588		12,044			9,905
	Accelerated depreciation		418		569		1,158			1,757
	Asset disposal		199		—		295			915
	Total		$	6,195	$	10,505	$	29,130		$	40,766
	Total restructuring and transformation		$	12,909	$	17,500	$	51,247		$	69,889

COMPREHENSIVE_INCOME_Tables

COMPREHENSIVE INCOME (Tables)	9 Months Ended
	Dec. 27, 2014
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The following is a roll-forward of the components of Accumulated Other Comprehensive Income, net of tax, for the nine months ended December 27, 2014:
	(In thousands)	Foreign Currency			Defined Benefit Plans			Net Unrealized (Gain)/Loss on Derivatives			Total
	Balance as of March 29, 2014	$	3,198		$	(4,592	)	$	2,804		$	1,410
	Other comprehensive income (loss)/income before reclassifications	(13,621		)	(597		)	8,154			(6,064		)
	Amounts reclassified from Accumulated Other Comprehensive Income	—			—			(2,921		)	(2,921		)
	Net current period other comprehensive (loss)/income	(13,621		)	(597		)	5,233			(8,985		)
	Balance as of December 27, 2014	$	(10,423	)	$	(5,189	)	$	8,037		$	(7,575	)
Reclassification out of Accumulated Other Comprehensive Income	Details pertaining to the amount reclassified from Accumulated Other Comprehensive Income for the nine months ended December 27, 2014 are as follows:
	(In thousands)	Amounts Reclassified from Other Comprehensive Income			Affected Line in the
					Statement of Income
	Derivative instruments reclassified to income statement
	Realized net gain on derivatives	$	3,041		Revenue, cost of goods sold, income/(expense)
	Income tax effect	(120		)	Provision for income taxes
	Net of taxes	$	2,921

BASIS_OF_PRESENTATION_Narrativ

BASIS OF PRESENTATION (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013	Dec. 27, 2014	Dec. 28, 2013	Mar. 29, 2014
Term of each fiscal year			364 days		364 days
Term of each quarter			91 days		91 days
Total operating expenses	$93,401	$103,769	$297,051	$318,243
Operating Expenses Would Be Higher [Member]
Total operating expenses	$1,700		$1,700

EARNINGS_PER_SHARE_EPS_Schedul

EARNINGS PER SHARE ("EPS") (Schedule of Earnings Per Share Reconciliation) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013	Dec. 27, 2014	Dec. 28, 2013
Basic EPS
Net income	$15,988	$16,290	$19,827	$24,964
Basic weighted average shares (in shares)	51,432,000	51,730,000	51,521,000	51,485,000
Basic income per share (in dollars per share)	$0.31	$0.31	$0.38	$0.48
Diluted EPS
Net income	$15,988	$16,290	$19,827	$24,964
Basic weighted average shares (in shares)	51,432,000	51,730,000	51,521,000	51,485,000
Net effect of common stock equivalents (in shares)	530,000	781,000	503,000	815,000
Diluted weighted average shares (in shares)	51,962,000	52,511,000	52,024,000	52,300,000
Diluted income per share (in dollars per share)	$0.31	$0.31	$0.38	$0.48
Stock options excluded from computation of weighted average shares outstanding (in shares)	1,700,000	1,300,000	1,600,000	900,000

STOCKBASED_COMPENSATION_Detail

STOCK-BASED COMPENSATION (Details) (USD $)	9 Months Ended		0 Months Ended
	Dec. 27, 2014	Dec. 28, 2013	Oct. 22, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	$10,219,000	$9,664,000
Tax benefit from compensation expense	3,300,000	3,200,000
Weighted average fair value of options granted (in dollars per share)	$7.89	$10.17
Total unrecognized compensation cost	29,000,000
Total unrecognized compensation cost related to non-vested stock options, weighted average period of recognition	2 years 7 months 10 days
Stock Options Black-Scholes assumptions (weighted average):
Volatility	22.45%	22.79%
Expected life (years)	4 years 10 months 24 days	4 years 10 months 24 days
Risk-free interest rate	1.75%	1.30%
Dividend yield	0.00%	0.00%
Shares purchased under the ESPP (in shares)	183,808	156,224
Shares purchased under the ESPP (in dollars per share)	$25.92	$32.77
2005 Long-Term Incentive Compensation Plan [Member] | Performance Shares [Member] | Senior Executives [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)			129,130
Number of individuals			14
Performance payout percentage			100.00%
Stock price correlation period			3 years
Dividend history			12 months
Stock-based compensation expense recognized	278,000
PSU Award Fair Value (in dollars per share)	$35.09
Total unrecognized compensation cost	$4,253,000
Stock Options Black-Scholes assumptions (weighted average):
Volatility			20.00%
Risk-free interest rate			0.78%
2005 Long-Term Incentive Compensation Plan [Member] | Performance Shares [Member] | Senior Executives [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)			0
Performance payout percentage			0.00%
2005 Long-Term Incentive Compensation Plan [Member] | Performance Shares [Member] | Senior Executives [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)			258,260
Performance payout percentage			200.00%

PRODUCT_WARRANTIES_Schedule_of

PRODUCT WARRANTIES (Schedule of Product Warranty Liability) (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013
Product Warranties [Roll Forward]
Warranty accrual as of the beginning of the period	$590	$673
Warranty provision	890	1,214
Warranty spending	-941	-1,178
Warranty accrual as of the end of the period	$539	$709

INVENTORIES_Schedule_of_Invent

INVENTORIES (Schedule of Inventories) (Details) (USD $)	Dec. 27, 2014	Mar. 29, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$74,555	$72,508
Work-in-process	6,431	7,383
Finished goods	131,507	117,770
Inventories, net	$212,493	$197,661

DERIVATIVES_AND_FAIR_VALUE_MEA2

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013
Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	($8,409)	($5,000)
Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contract | Net revenues, COGS, and SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	2,921	7,100
Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contract | Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	107
Designated as Hedging Instrument | Interest Rate Swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	255
Amount Excluded from Effectiveness Testing	0
Designated as Hedging Instrument | Interest Rate Swap [Member] | Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	0
Not Designated as Hedging Instrument | Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	0
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	0
Not Designated as Hedging Instrument | Foreign Exchange Contract | Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	$5,477

DERIVATIVES_AND_FAIR_VALUE_MEA3

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets) (Details) (USD $)	Dec. 27, 2014	Mar. 29, 2014
In Thousands, unless otherwise specified
Derivative Assets:
Derivative Assets	$8,929	$3,824
Derivative Liabilities:
Derivative Liabilities	2,465	1,255
Designated as Hedging Instrument | Foreign Exchange Contract | Other Current Assets
Derivative Assets:
Derivative Assets	8,088	2,574
Designated as Hedging Instrument | Foreign Exchange Contract | Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	2,465	1,255
Designated as Hedging Instrument | Interest Rate Swap [Member] | Other Current Assets
Derivative Assets:
Derivative Assets	$841	$1,250

DERIVATIVES_AND_FAIR_VALUE_MEA4

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Financial Assets and Financial Liabilities Measured at Fair Value) (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Dec. 27, 2014
Assets
Money market funds	$72,875
Designated foreign currency hedge contracts	8,088
Designated interest rate swap	841
Assets, Fair Value Disclosure, Total	81,804
Liabilities
Designated foreign currency hedge contracts	2,465
Contingent consideration	8,351
Liabilities, Fair Value Disclosure	10,816
Quoted Market Prices for Identical Assets (Level 1)
Assets
Money market funds	72,875
Designated foreign currency hedge contracts	0
Designated interest rate swap	0
Assets, Fair Value Disclosure, Total	72,875
Liabilities
Designated foreign currency hedge contracts	0
Contingent consideration	0
Liabilities, Fair Value Disclosure	0
Significant Other Observable Inputs (Level 2)
Assets
Money market funds	0
Designated foreign currency hedge contracts	8,088
Designated interest rate swap	841
Assets, Fair Value Disclosure, Total	8,929
Liabilities
Designated foreign currency hedge contracts	2,465
Contingent consideration	0
Liabilities, Fair Value Disclosure	2,465
Significant Unobservable Inputs (Level 3)
Assets
Money market funds	0
Designated foreign currency hedge contracts	0
Designated interest rate swap	0
Assets, Fair Value Disclosure, Total	0
Liabilities
Designated foreign currency hedge contracts	0
Contingent consideration	8,351
Liabilities, Fair Value Disclosure	8,351
Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Contingent consideration as of March 29, 2014	7,645
Contingent consideration interest expense	706
Ending balance	$8,351

DERIVATIVES_AND_FAIR_VALUE_MEA5

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Narrative) (Details) (USD $)	9 Months Ended		0 Months Ended
	Dec. 27, 2014	Dec. 28, 2013	Dec. 21, 2012	Mar. 29, 2014	Jun. 28, 2014
Derivative [Line Items]
Percentage of sales generated outside the US	45.90%
Maturity period for foreign currency contracts (in years)	1 year
Designated foreign currency hedge contracts outstanding	$147,400,000			$157,900,000
Gains reclassified to AOCI in next 12 months	8,400,000
Non-designated foreign currency hedge contracts outstanding	60,400,000			72,900,000
Term Loan [Member]
Derivative [Line Items]
Face amount of debt					475,000,000
Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Deferred income tax expense (benefit)	500,000
Designated as Hedging Instrument | Interest Rate Swap [Member]
Derivative [Line Items]
Deferred income tax expense (benefit)	300,000
Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contract
Derivative [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	8,409,000	5,000,000
Designated as Hedging Instrument | Interest Rate Swap [Member]
Derivative [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	-255,000
Description of variable rate basis			LIBOR
Derivative, fixed interest rate			0.68%
Notional amount of derivative			250,000,000
Net revenues, COGS, and SG&A | Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contract
Derivative [Line Items]
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	$2,921,000	$7,100,000

INCOME_TAXES_Details

INCOME TAXES (Details)	9 Months Ended
	Dec. 27, 2014	Dec. 28, 2013
Income Tax Disclosure [Abstract]
Reported tax rate	7.80%	6.30%

DEBT_Details

DEBT (Details) (USD $)	3 Months Ended
	Jun. 28, 2014	Dec. 27, 2014	Jun. 30, 2014
Debt Instrument [Line Items]
Debt outstanding		$429,406,000
2015		0
2016		21,342,000
2017		42,683,000
2018		45,054,000
2019 and beyond		320,327,000
Credit Agreement [Member]
Debt Instrument [Line Items]
Term of credit facilities	5 years
Debt outstanding		429,400,000
Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Effective interest rate			1.56%
Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument [Line Items]
Interest Rate	1.13%
Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument [Line Items]
Interest Rate	1.50%
Term Loan [Member]
Debt Instrument [Line Items]
Face amount of debt	475,000,000
Debt outstanding			379,400,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Face amount of debt	50,000,000
Debt outstanding			50,000,000
Maximum borrowing capacity			100,000,000

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Dec. 27, 2014
In Millions, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]
Damages claimed	$4.10

SEGMENT_INFORMATION_Details

SEGMENT INFORMATION (Details)	9 Months Ended
	Dec. 27, 2014
	segment
Segment Reporting [Abstract]
Number of reportable segments	1

RESTRUCTURING_Narrative_Detail

RESTRUCTURING (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Dec. 27, 2014	Dec. 28, 2013	Dec. 27, 2014	Dec. 28, 2013
Restructuring Cost and Reserve [Line Items]
Expected cost	$69,000,000		$69,000,000
Expected cost in cash			59,000,000
Restructuring Costs Incurred	6,195,000	10,505,000	29,130,000	40,766,000
Transformation costs	6,714,000	6,995,000	22,117,000	29,123,000
Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Expected cost	10,000,000		10,000,000
Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Expected cost	$15,000,000		$15,000,000

RESTRUCTURING_Schedule_of_Rest

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013	Dec. 27, 2014	Dec. 28, 2013
Restructuring Reserve [Roll Forward]
Restructuring Accrual Balance			$23,636	$3,262
Restructuring Costs Incurred	6,195	10,505	29,130	40,766
Less Payments			-34,312	-19,256
Less Non-Cash Adjustments			1,453	2,672
Restructuring Accrual Balance	17,001	22,100	17,001	22,100
Severance and other employee costs
Restructuring Reserve [Roll Forward]
Restructuring Accrual Balance			22,908	3,089
Restructuring Costs Incurred	2,887	5,348	15,633	28,189
Less Payments			-21,785	-9,690
Less Non-Cash Adjustments			0	0
Restructuring Accrual Balance	16,756	21,588	16,756	21,588
Other costs
Restructuring Reserve [Roll Forward]
Restructuring Accrual Balance			728	173
Restructuring Costs Incurred	2,691	4,588	12,044	9,905
Less Payments			-12,527	-9,566
Less Non-Cash Adjustments			0	0
Restructuring Accrual Balance	245	512	245	512
Accelerated depreciation
Restructuring Reserve [Roll Forward]
Restructuring Accrual Balance			0	0
Restructuring Costs Incurred	418	569	1,158	1,757
Less Payments			0	0
Less Non-Cash Adjustments			-1,158	-1,757
Restructuring Accrual Balance	0	0	0	0
Asset write-down
Restructuring Reserve [Roll Forward]
Restructuring Accrual Balance			0	0
Restructuring Costs Incurred			295	915
Less Payments			0	0
Less Non-Cash Adjustments			-295	-915
Restructuring Accrual Balance	$0	$0	$0	$0

RESTRUCTURING_Schedule_of_Rest1

RESTRUCTURING (Schedule of Restructuring and Related Costs) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013	Dec. 27, 2014	Dec. 28, 2013
Restructuring Cost and Reserve [Line Items]
Transformation costs	$6,714	$6,995	$22,117	$29,123
Restructuring Costs Incurred	6,195	10,505	29,130	40,766
Total restructuring and transformation	12,909	17,500	51,247	69,889
Severance and other employee costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs Incurred	2,887	5,348	15,633	28,189
Other costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs Incurred	2,691	4,588	12,044	9,905
Accelerated depreciation
Restructuring Cost and Reserve [Line Items]
Restructuring Costs Incurred	418	569	1,158	1,757
Asset disposal
Restructuring Cost and Reserve [Line Items]
Restructuring Costs Incurred	199	0	295	915
Transformation and other costs
Restructuring Cost and Reserve [Line Items]
Transformation costs	5,892	6,306	20,877	26,389
Accelerated depreciation
Restructuring Cost and Reserve [Line Items]
Transformation costs	351	653	769	1,938
Asset disposal
Restructuring Cost and Reserve [Line Items]
Transformation costs	$471	$36	$471	$796

CAPITALIZATION_OF_SOFTWARE_DEV1

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS (Narrative) (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013	Mar. 29, 2014
Research and Development [Abstract]
Capitalized software development costs for ongoing initiatives	($6.60)	$3.40
Software costs capitalized, net	38.3		31.7
Total costs capitalized related to in process software development initiatives	8.9		15.6
Capitalized software development costs placed into service	$12.90

ACCUMULATED_OTHER_COMPREHENSIV1

ACCUMULATED OTHER COMPREHENSIVE INCOME (Details 1) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Dec. 27, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance as of March 29, 2014	$1,410
Other comprehensive income (loss)/income before reclassifications	-6,064
Amounts reclassified from Accumulated Other Comprehensive Income	-2,921
Net current period other comprehensive (loss)/income	-8,985
Balance as of December 27, 2014	-7,575
Foreign Currency
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance as of March 29, 2014	3,198
Other comprehensive income (loss)/income before reclassifications	-13,621
Amounts reclassified from Accumulated Other Comprehensive Income	0
Net current period other comprehensive (loss)/income	-13,621
Balance as of December 27, 2014	-10,423
Defined Benefit Plans
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance as of March 29, 2014	-4,592
Other comprehensive income (loss)/income before reclassifications	-597
Amounts reclassified from Accumulated Other Comprehensive Income	0
Net current period other comprehensive (loss)/income	-597
Balance as of December 27, 2014	-5,189
Net Unrealized (Gain)/Loss on Derivatives
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance as of March 29, 2014	2,804
Other comprehensive income (loss)/income before reclassifications	8,154
Amounts reclassified from Accumulated Other Comprehensive Income	-2,921
Net current period other comprehensive (loss)/income	5,233
Balance as of December 27, 2014	$8,037

ACCUMULATED_OTHER_COMPREHENSIV2

ACCUMULATED OTHER COMPREHENSIVE INCOME (Details 2) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013	Dec. 27, 2014	Dec. 28, 2013
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Realized net gain on derivatives	($2,308)	($2,852)	($7,496)	($8,035)
Income tax effect	36	1,282	-1,679	-1,682
Net income	15,988	16,290	19,827	24,964
Net Unrealized (Gain)/Loss on Derivatives | Amounts Reclassified from Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Realized net gain on derivatives			3,041
Income tax effect			-120
Net income			$2,921